Advertisement

Topics

Minerva Biotechnologies Company Profile

05:06 EDT 22nd March 2019 | BioPortfolio

Minerva Biotechnologies is a pioneer in the field of stem cells and cancer stem cells. Minerva was first to discover that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star). By studying human stem cells in parallel with human cancer cells, Minerva scientists figured out how cancer cells override the normal ‘shut off’ switch that stops stem cells from self-replicating indefinitely. The Company is developing a panel of anti-cancer drugs that target a cancer-specific MUC1* growth factor receptor and a testis specific cancer antigen that promotes metastasis.


News Articles [166 Associated News Articles listed on BioPortfolio]

Minerva Neurosciences, Inc: Minerva Neurosciences to Host Webcast Event on Schizophrenia

Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone's potential positio...

Minerva Neurosciences, Inc: Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018

WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat ...

Minerva Neurosciences, Inc: Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates

Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical c...

Minerva Neurosciences, Inc: Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018

Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone ...

DGAP-Stimmrechte: Elanix Biotechnologies AG (deutsch)

Elanix Biotechnologies AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung DGAP Stimmrechtsmitteilung: Elanix Biotechnologies AG Elanix Biotechnologies AG: Veröf...

Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates

Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia di...

Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers

WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou...

Minerva Neurosciences, Inc: Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers

Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe...

Drugs and Medications [0 Results]

None

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure

The aim of this study is to test the impact of the managed ventricular pacing (MVP) mode and atrial preventive and antitachycardia pacing therapies on the reduction of a composite clinical...

A Two-Phase Clinical Study of the Minerva AURORA Ablation System

The primary objective of this study is to evaluate the use of the Aurora Ablation System in reducing menstrual blood loss at 12 months post-treatment. The occurrence of adverse events wil...

Development and Evaluation of Hygie, a New Serious Game for Continuing Medical Education of General Practitioners

We produced a prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Pr...

Companies [109 Associated Companies listed on BioPortfolio]

Minerva Biotechnologies

Minerva Biotechnologies is a pioneer in the field of stem cells and cancer stem cells. Minerva was first to discover that cancer cells hijack an otherwise normal stem cell growth ...

Minerva Pharmaceuticals

Minerva Pharmaceuticals, Inc. is a biopharmaceutical product development company dedicated to detecting and eliminating cancer before clinical symptoms occur.

RAN Biotechnologies

Based in Beverly, MA, USA, RAN Biotechnologies, Inc., www.ranbiotechnologies.com, provides chemicals specially optimized for microfluidic and biotechnological applications. Partic...

Minerva Biolabs GmbH

Minerva Biolabs is committed to providing highest quality in products and services.1999 The company was established in August 1999 as a spin-off from the Robert-Koch Institute (RKI) in Berlin. Minerva...

Minerva Holdings Inc.

More Information about "Minerva Biotechnologies" on BioPortfolio

We have published hundreds of Minerva Biotechnologies news stories on BioPortfolio along with dozens of Minerva Biotechnologies Clinical Trials and PubMed Articles about Minerva Biotechnologies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Minerva Biotechnologies Companies in our database. You can also find out about relevant Minerva Biotechnologies Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record